个人简介

2009年博士毕业于中国医学科学院&北京协和医学院肿瘤研究所分子肿瘤学国家重点实验室,毕业后在中日友好医院临床医学研究所工作至今。期间2015年9月至2016年12月在美国耶鲁大学医学院GeraldI.Shulman院士实验室作访问学者。主要研究方向为肥胖、非酒精性脂肪肝、糖尿病等代谢性疾病的发病机制研究。以通讯或第一作者在SCI杂志Cell Metabolism、Metabolism、Pharmacological Research、International Journal of Biological Sciences、Phytomedicine、JBC、FASEB Journal、Molecular Nutrition &Food Research、Journal of Nutritional Biochemistry、Life Science、Carcinogenesis、Journal of Endocrinology 及JBC等发表论著36篇(累计IF=247,单篇最高IF=20.6,单篇最高引用228次),主持“国家自然科学基金”4项、“北京自然科学基金”3项、“首都卫生发展科研专项”1项、“中国医学科学院青年医学人才奖励项目”1项、“北京市研究型病房建设临床研究项目”1项、“北京化工大学-中日友好医院生物医学转化工程研究中心联合项目”1项、“中日友好医院高水平医院临床业务费专项”2项、“中日医院菁英计划-拔尖人才”1项以及“中日医院青年科技英才课题”1项。

研究方向

主要研究方向为肥胖、非酒精性脂肪肝、糖尿病等代谢性疾病的发病机制和药物防治研究

合作或招生需求

1.常年招收基础医学、病理生理学、中西医结合基础、药理学等专业联合培养研究生。

2.研究生需对科研有较强的兴趣、勤奋努力、良好的沟通能力。

联系方式:pengliang8028@163.com

近年代表性学术论文(第一或通讯作者)

1. Perry RJ#, Peng L#, Cline GW, Petersen KF, Shulman GI: A Non-invasive Method to Assess Hepatic Acetyl-CoA In Vivo. Cell Metab 2017, 25(3): 749-756.

2. Wang S, Wang Y, Lin L, Li Z, Liu F, Zhu L, Chen J, Zhang N, Cao X, Ran S, Liu G, Gao P, Sun W, Peng L*, Zhuang J*, Meng H*: Layer-Specific BTX-A Delivery to the Gastric Muscularis Achieves Effective Weight Control and Metabolic Improvement. Adv Sci (Weinh). 2023 Oct;10(28): e2300822

3. Zhang H, Lu J, Liu H, Guan L, Xu S, Wang Z, Qiu Y, Liu H, Peng L*, Men X#*: Ajugol enhances TFEB-mediated lysosome biogenesis and lipophagy to alleviate non-alcoholic fatty liver disease. Pharmacol Res 2021, 174:105964.

4. Liu T, Li Q, Jin Q, Yang L, Mao H, Qu P, Guo J, Zhang B, Ma F, Wang Y, Peng L*, Li P*, Zhan Y*.Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease. Int J Biol Sci. 2023 Sep 25;19(15):5020-5035

5. Zhai Y, Zhou W, Yan X, Qiao Y, Guan L, Zhang Z, Liu H, Jiang J, Liu J*, Peng L*. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling. Phytomedicine. 2022 Dec; 107: 154444.

6. Zhou W, Yan X, Zhai Y, Liu H, Guan L, Qiao Y, Jiang J*, Peng L*. Phillygenin ameliorates nonalcoholic fatty liver disease via TFEB-mediated lysosome biogenesis and lipophagy. Phytomedicine. 2022 Aug; 103: 154235.

7. Zhang Z, Qiao Y, Sun Q, Peng L*, Sun L*.A novel SLC25A1 inhibitor, parthenolide, suppresses the growth and stemness of liver cancer stem cells with metabolic vulnerability. Cell Death Discov. 2023 Sep 23;9(1):350.

8. Yan X, Zhai Y, Zhou W, Qiao Y, Guan L, Liu H, Jiang J*, Peng L*. Intestinal Flora Mediates Antiobesity Effect of Rutin in High-Fat-Diet Mice. Mol Nutr Food Res. 2022 Jul;66(14):e2100948.

9. Liu H, Guo L,Zhang H, Zhou WL,Guan LL,Yan X, Zhai YY,Qiao Y,Wang Z,Wang HT*,Peng L*.Quercetin protects against palmitate-induced pancreatic β-cell apoptosis by restoring lysosomal function and autophagic flux. J Nutr Biochem. 2021,35: 652-659.

10. Wang Y, Liu H, Zhang R, Xiang Y, Lu J, Xia B*, Peng L*, Wu J*. AdipoRon exerts opposing effects on insulin sensitivity via fibroblast growth factor 21-mediated time-dependent mechanisms. J Biol Chem. 2022 Mar;298(3):101641.

11. Li Z，Liu D, Gu R, Qiao Y, Jin Q, Zhang Y, Ran S, Liu X,Wang Y,Mao N,Qin Y, Peng L*, Wang J*.Fecal microbiota transplantation in obesity metabolism: A meta analysis and systematic review. Diabetes Res Clin Pract. 2023 Aug: 202:110803.

12. Jin Q, Liu T, Qiao Y, Liu D, Yang L, Mao H, Ma F, Wang Y, Peng L*, Zhan Y*. Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols. Front Immunol. 2023; 14: 1185317.

13. Jin Q, Liu T, Ma F, Yang L, Mao H, Wang Y, Li P, Peng L*, Zhan Y*. Therapeutic application of traditional Chinese medicine in kidney disease: Sirtuins as potential targets. Biomed Pharmacother. 2023 Sep 22:167:115499

14. Qiao Y, Guan LL, Zhai YY, Yan X, Zhou WL, Liu H, Zhang ZC, and Peng L* Apigenin alleviates obesity-associated metabolic syndrome by regulating the composition of the gut microbiome.  Front Microbiol. 2021:11: 52-59.

15. Wang Z, Lu J, Zhou J, Sun W, Qiu Y, Chen W, Gao Y, Yang R, Ai S, Liu Z，Wang Y and Peng L*: Modulation of the Gut Microbiota by Shen-Yan-Fang-Shuai Formula Improves Obesity Induced by High-Fat Diets. Front Microbiol 2020, 11:564376.

16. Lu JF, Zhu MQ, Zhang H, Liu H, Xia B, Wang YL, Shi X, Peng L*, Wu JW*: Neohesperidin attenuates obesity by altering the composition of the gut microbiota in high-fat diet-fed mice. FASEB J 2020, 34(9):12053-12071.

17. Xu S, Li J, Zhai M, Yao X, Liu H, Deng T, Cai H, Zhang W, Zhang W, Lou J，Peng L*: 1,25-(OH)2D3 protects Schwann cells against advanced glycation end products-induced apoptosis through PKA-NF-kappaB pathway. Life Sci 2019, 225:107-116.

18. Wang Y, Zhao H, Li X, Wang Q, Yan M, Zhang H, Zhao T, Zhang N, Zhang P, Peng L*，Li P*: Formononetin alleviates hepatic steatosis by facilitating TFEB-mediated lysosome biogenesis and lipophagy. J Nutr Biochem 2019, 73:108214.

19. Guo L, Liu P, Gao L, Wang Z, Huang S, Peng L*, Zhao Z. Chrtosan hydrogel, as a biological macromolecule-based drug delivery system for exosomes and microvesicles in regenerative medicine: a mini review. Cellulose. 2021 Nov 06

20. Wang Y, Zhao H, Li X, Li N, Wang Q, Liu Y, Liang Q, Shao Z, Zhang N, Zhao T，Peng L*，Li P*:  Tangshen Formula Alleviates Hepatic Steatosis by Inducing Autophagy Through the AMPK/SIRT1 Pathway. Front Physiol 2019, 10:494.

21. Gao Y, Yang R, Guo L, Wang Y, Liu WJ, Ai S, Woon TH, Wang Z, Zhai Y, Wang Z*，Peng L*: Qing-Re-Xiao-Zheng Formula Modulates Gut Microbiota and Inhibits Inflammation in Mice With Diabetic Kidney Disease. Front Med (Lausanne) 2021, 8:719950.

22. Xu S, Bao W, Men X, Liu Y, Sun J, Li J, Liu H, Cai H, Zhang W, Lou J, Peng L*: Interleukin-10 Protects Schwann Cells against Advanced Glycation End Products-Induced Apoptosis via NF-kappaB Suppression. Exp Clin Endocrinol Diabetes 2020, 128(2):89-96.

23. Song D, Chen Y, Wang X, Chen X, Gao S, Xu W, Yang S, Wang Z, Peng L*, Dai H*. A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization.J Vis Exp. 2023 Jan 20:(191). doi: 10.3791/64097.